[go: up one dir, main page]

EA200802104A1 - Применение композиций, содержащих антагонисты каппа-опиоидных рецепторов, для лечения диссоциативных расстройств - Google Patents

Применение композиций, содержащих антагонисты каппа-опиоидных рецепторов, для лечения диссоциативных расстройств

Info

Publication number
EA200802104A1
EA200802104A1 EA200802104A EA200802104A EA200802104A1 EA 200802104 A1 EA200802104 A1 EA 200802104A1 EA 200802104 A EA200802104 A EA 200802104A EA 200802104 A EA200802104 A EA 200802104A EA 200802104 A1 EA200802104 A1 EA 200802104A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
cappa
application
compositions containing
opioid receptors
Prior art date
Application number
EA200802104A
Other languages
English (en)
Other versions
EA014820B1 (ru
Inventor
Хольгер Ларс Герман
Original Assignee
Хольгер Ларс Герман
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006015733A external-priority patent/DE102006015733A1/de
Priority claimed from DE102006016991A external-priority patent/DE102006016991A1/de
Application filed by Хольгер Ларс Герман filed Critical Хольгер Ларс Герман
Publication of EA200802104A1 publication Critical patent/EA200802104A1/ru
Publication of EA014820B1 publication Critical patent/EA014820B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к применению композиции, включающей антагонисты каппа-опиоидных рецепторов, для изготовления лекарственного средства для лечения диссоциативных расстройств у людей.
EA200802104A 2006-04-04 2007-04-03 Применение композиций, содержащих антагонист каппа-опиоидных рецепторов бупренорфин, для лечения эмоционально неустойчивых расстройств личности EA014820B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006015733A DE102006015733A1 (de) 2006-04-04 2006-04-04 Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit
DE102006016991A DE102006016991A1 (de) 2006-04-11 2006-04-11 Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen
PCT/EP2007/053248 WO2007115975A2 (de) 2006-04-04 2007-04-03 Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen

Publications (2)

Publication Number Publication Date
EA200802104A1 true EA200802104A1 (ru) 2009-04-28
EA014820B1 EA014820B1 (ru) 2011-02-28

Family

ID=38110094

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200802104A EA014820B1 (ru) 2006-04-04 2007-04-03 Применение композиций, содержащих антагонист каппа-опиоидных рецепторов бупренорфин, для лечения эмоционально неустойчивых расстройств личности

Country Status (17)

Country Link
US (1) US8063059B2 (ru)
EP (1) EP2001456B1 (ru)
JP (1) JP5128578B2 (ru)
AT (1) ATE450256T1 (ru)
AU (1) AU2007236003B2 (ru)
CA (1) CA2646899C (ru)
CY (1) CY1109862T1 (ru)
DE (1) DE502007002185D1 (ru)
DK (1) DK2001456T3 (ru)
EA (1) EA014820B1 (ru)
ES (1) ES2337622T3 (ru)
HR (1) HRP20100113T1 (ru)
PL (1) PL2001456T3 (ru)
PT (1) PT2001456E (ru)
RS (1) RS51211B (ru)
SI (1) SI2001456T1 (ru)
WO (1) WO2007115975A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2679661C1 (ru) * 2013-12-20 2019-02-12 Х. Лундбекк А/С Применение антагониста опиоидных рецепторов с k-активностью и вортиоксетина для лечения депрессивного расстройства с меланхолическими признаками

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2252581E (pt) 2008-01-22 2012-08-31 Lilly Co Eli Antagonista selectivo de receptores kapa de opióides
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same
AU2015253434B2 (en) 2014-04-28 2018-12-13 Dimerx, Inc. Buprenorphine dimer and its use in treatment of gastrointestinal disorders
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
KR20240156409A (ko) 2022-03-07 2024-10-29 얀센 파마슈티칼즈, 인코포레이티드 주요 우울 장애 치료에 사용을 위한 아티카프란트의 다형 형태
EP4489730A1 (en) 2022-03-07 2025-01-15 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028612A (en) * 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
WO1999045906A1 (en) * 1998-03-09 1999-09-16 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
EP1365756A2 (en) * 2000-08-15 2003-12-03 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
US20020045572A1 (en) * 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
EP1353665A4 (en) * 2000-12-21 2004-05-06 Mclean Hospital Corp Treatment of depression
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
EP1613617A4 (en) * 2003-04-04 2009-02-18 Merck & Co Inc METABOTROPIC GLUTAMATE RECEPTOR-5 DIARYLSUBSTITUTED TRIAZOLE MODULATORS
BRPI0508254A (pt) * 2004-03-02 2007-07-24 Pharmacia Corp métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
EA011826B1 (ru) * 2004-05-26 2009-06-30 Инотек Фармасьютикалз Корпорейшн Пуриновые производные в качестве агонистов аденозиновых арецепторов и способы их применения
DE602004017514D1 (de) * 2004-06-02 2008-12-11 Galephar M F Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2679661C1 (ru) * 2013-12-20 2019-02-12 Х. Лундбекк А/С Применение антагониста опиоидных рецепторов с k-активностью и вортиоксетина для лечения депрессивного расстройства с меланхолическими признаками

Also Published As

Publication number Publication date
SI2001456T1 (sl) 2010-04-30
JP2009532434A (ja) 2009-09-10
AU2007236003B2 (en) 2012-10-18
HRP20100113T1 (hr) 2010-04-30
CY1109862T1 (el) 2014-09-10
EP2001456B1 (de) 2009-12-02
CA2646899C (en) 2014-05-06
WO2007115975A2 (de) 2007-10-18
PT2001456E (pt) 2010-03-03
US8063059B2 (en) 2011-11-22
DK2001456T3 (da) 2010-04-12
CA2646899A1 (en) 2007-10-18
WO2007115975A3 (de) 2008-02-14
EA014820B1 (ru) 2011-02-28
US20090181999A1 (en) 2009-07-16
RS51211B (sr) 2010-12-31
ATE450256T1 (de) 2009-12-15
AU2007236003A1 (en) 2007-10-18
EP2001456A2 (de) 2008-12-17
PL2001456T3 (pl) 2010-05-31
ES2337622T3 (es) 2010-04-27
DE502007002185D1 (de) 2010-01-14
JP5128578B2 (ja) 2013-01-23

Similar Documents

Publication Publication Date Title
ATE469895T1 (de) Cgrp-rezeptorantagonisten
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
MX2009006304A (es) Nuevos compuestos de oxadiazol.
ME01532B (me) Jedinjenja
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
DE602007012072D1 (de) Orantagonisten
CY1110882T1 (el) Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης
CL2009000171A1 (es) Compuestos derivados de 1-oxa-3-azaespiro, antagonistas del receptor y5 de neuropeptido y (npy); composicion farmaceutica que comprende dicho compuesto; y uso para el tratamiento de trastornos de la alimentacion, trastornos de la bebida, obesidad y depresion.
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
MA32568B1 (fr) Formulations pharmaceutiques contenant des ligands de recepteur de dopamine
EP2121658A4 (en) PIPERAZINYLPROPYLPYRAZOL DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BRPI0715893A2 (pt) composto de azetidina e uso para a preparaÇço de um medicamento para a prevenÇço ou tratamento de distérbios distÍmicos ou do sono
EA200802104A1 (ru) Применение композиций, содержащих антагонисты каппа-опиоидных рецепторов, для лечения диссоциативных расстройств
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
EP1962838A4 (en) Farnesoid X RECEPTOR AGONISTS
ATE483707T1 (de) 2-cyclopropylthiazolderivate
EP2170064A4 (en) 6,5-pyrrolopiperidine tachykinin receptor antagonists
MA32774B1 (fr) Antagonistes de récepteur de mélanocortine
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
HK1120442A1 (en) Novel opioid antagonists
MA32622B1 (fr) Derives de carbonate de quinuclidine et composition medicinale les comprenant
EA201171074A1 (ru) Цитотоксические конъюгаты с соединением, связывающим рецептор нейропептида y
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU